People's Justice

Case updates

Zantac state cases: what does the Delaware order show?

Delaware’s April 14, 2026 order ended a defined group of Zantac claims. It does not describe every state or certify the latest appeal.

See If You Qualify

Free · No obligation · About 2 minutes

Updated Oct 4, 202613 sources

This may apply to you if

  • Preparation suggestions only; no cancer list, use-duration threshold or current firm acceptance rule is verified.
  • Describe the product, dates and diagnosis you want checked.
  • Ask a lawyer what evidence and court route apply to your own situation.

What the public record says

These are cited sources. Their inclusion does not imply that they endorse People’s Justice or reviewed this page.

Francis J. Jones, Jr. · Superior Court of the State of Delaware · Superior Court judge signing the cited order

Finding: The April order grants judgment for defendants for consolidated complaints filed on or before December 1, 2025; later-filed evidence is addressed separately.

Jones: April14,2026 Delaware Zantac order (opens in a new tab) · Apr 14, 2026 · Checked Oct 4, 2026

The evidence and its limits

Yonsei University College of Medicine, first-author affiliation · JAMA Network Open · 2023

Ranitidine Use and Incident Cancer in a Multinational Cohort

Design:
Cohort
Participants:
1,183,999 eligible people across eleven analytical databases: 909,168 new ranitidine users and 274,831 other H2-blocker users. Primary meta-analysis used four databases meeting stricter balance criteria.
Finding:
The primary and broader comparisons did not show a statistically significant overall cancer increase relative to other H2 blockers.
Main limitation
Prescription or dispensing data do not capture all actual or nonprescription use; individual impurity and dietary exposure were not measured. Follow-up may miss long-latency effects and rare or small differences. The paper reports distinct primary, broader and calibrated estimates; no pooled number is presented as one universal eleven-database result. No individual cause or universal safety finding.

Read the source: Ranitidine Use and Incident Cancer in a Multinational Cohort (opens in a new tab) · Checked Oct 4, 2026

Tainan Municipal Hospital, first-author affiliation · International Journal of Environmental Research and Public Health · 2022

Pharmacoepidemiological research on NDMA-contaminated ranitidine use and long-term cancer risk

Design:
Cohort
Participants:
55,110 ranitidine users and 55,110 matched untreated people; additional drug-comparison analyses are separate.
Finding:
Several cancer rates were higher in the ranitidine group compared with untreated controls.
Main limitation
Observational matching cannot balance unknown factors. Personal impurity, smoking, alcohol and complete actual use were unavailable. Authors declared no conflicts and no funder role; that is not a review or endorsement of PJ.

Read the source: Pharmacoepidemiological research on NDMA-contaminated ranitidine use and long-term cancer risk (opens in a new tab) · Checked Oct 4, 2026

The short answer

What changed in the April 2026 Delaware order?
The judge ruled for the drug companies in a defined group of claims. The issue was whether the required evidence showed the drug can cause the diseases. [8]
What are the key dates in these orders?
A complaint means the paper starting a lawsuit. The April order uses its filed date. It includes filings on December 1, 2025. [8]
Does it guarantee a path for later filings?
No. The opinion discusses further evidence for later-filed cases. That is not a promise that a firm accepts new claims or that a person will win. [8]
Does a case count tell me whether I am included?
The order defines its scope by filed claims and evidence. A headline count does not identify your case or show that you are eligible. [8]

The process

What happens next

  1. 01

    You answer a few questions

    About two minutes. Nothing is sent until you agree on the last step and press submit.

  2. 02

    A lawyer looks at it

    A lawyer at the firm reads your answers and checks them against the current case criteria.

  3. 03

    The firm decides and gets in touch

    If the firm takes your case, you get the terms in writing to read before you sign. You can always say no.

  1. DATE

    TAG

    Settlement

    WHAT HAPPENED

    GSK announced agreements with 10 plaintiff firms representing ~80,000 claimants (93% of pending US state-court Zantac cases) to pay up to $2.2 billion in aggregate, with full implementation expected by end of H1 2025; GSK admitted no liability.

    SOURCE

    us.gsk.com

  2. DATE

    TAG

    Settlement

    WHAT HAPPENED

    Sanofi agreed to pay more than $100 million to settle ~4,000 Zantac cancer suits in state courts outside Delaware — the first major resolution in the litigation, averaging more than $25,000 per claim per Bloomberg's reporting (republished by Insurance…

    SOURCE

    insurancejournal.com

  3. DATE

    TAG

    Court ruling

    WHAT HAPPENED

    MDL 2924 (S.D. Fla., Judge Robin L. Rosenberg) omnibus Daubert order (Doc 6120, 341 pages): ALL defendants' Daubert motions on general causation GRANTED and defendants' summary judgment motion GRANTED — plaintiffs 'fail to produce admissible primary evidence…

    SOURCE

    gsk.com

Delaware’s April 14, 2026 order ended a defined group of Zantac claims. It does not describe every state or certify the latest appeal. Check the exact court and filing date.

What changed in the April 2026 Delaware order?

The judge ruled for the drug companies in a defined group of claims. The issue was whether the required evidence showed the drug can cause the diseases.

The signed April 14 order applies to consolidated complaints filed on or before December 1, 2025. It is not a trial award to a patient or proof that every national claim had the same outcome.

What are the key dates in these orders?

A complaint means the paper starting a lawsuit. The April order uses its filed date. It includes filings on December 1, 2025.

Do not replace that exact boundary with before December 1. Diagnosis and medicine-use dates answer other questions. A lawyer can compare the actual filing papers with the order’s defined group.

Does it guarantee a path for later filings?

No. The opinion discusses further evidence for later-filed cases. That is not a promise that a firm accepts new claims or that a person will win.

Further procedure was left for additional work. The dated opinion does not certify completion of that work, every later appeal or the current status of a specific case. Ask for the controlling record.

Does a case count tell me whether I am included?

The order defines its scope by filed claims and evidence. A headline count does not identify your case or show that you are eligible.

Use the actual case number and filing papers for a check. The January 29, 2026 Delaware decision concerns a specified set of filing-time disputes, which is a separate issue from the April evidence ruling.

Are the state and federal rulings interchangeable?

No. The federal order has its own cancer groups and rules. The later state order has a different scope.

FDA’s older withdrawal was a product-safety action, not a national court award. The original studies also have differing findings and limits. A safety notice alone does not settle a state court’s scientific-evidence issue.

What does the dated court log show?

Ask for the court, filed date and actual order that applies to you. A state headline does not supply a national deadline or a payment schedule.

January 29, 2026: Delaware ruled on specified filing-time disputes. April 14, 2026: it ruled on the required evidence for claims filed on or before December 1, 2025. Ask which actual order and later proceedings control your own case.

Full timeline

From court orders and filings. Dates marked scheduled can move.

  1. Dec 6, 2022

    MDL 2924 (S.D. Fla., Judge Robin L. Rosenberg) omnibus Daubert order (Doc 6120, 341 pages): ALL defendants' Daubert motions on general… gsk.com

  2. Apr 23, 2024

    Sanofi agreed to pay more than $100 million to settle ~4,000 Zantac cancer suits in state courts outside Delaware — the first major… insurancejournal.com

  3. Oct 9, 2024

    GSK announced agreements with 10 plaintiff firms representing ~80,000 claimants (93% of pending US state-court Zantac cases) to pay up to… us.gsk.com

Follow this case

Get Zantac claim: what to ask and what to do case updates

One email when something changes: a ruling, a deadline, a settlement step. Nothing else.

Find out where you stand.

The review is free and private. Asking for it doesn’t commit you to anything.

Register your interest

Sources

  1. ABA Model Rule 1.5: feesABA Model Rule 1.5: fees
  2. Southern District of New York: time limitsSouthern District of New York: time limits · court
  3. 45 CFR 164.524: access to health records45 CFR 164.524: access to health records · regulator
  4. FDA: April2020 ranitidine withdrawal requestFDA: April2020 ranitidine withdrawal request · regulator
  5. FDA: reformulated ranitidine approvalFDA: reformulated ranitidine approval · regulator
  6. You: original multinational ranitidine cancer cohortYou: original multinational ranitidine cancer cohort · study
  7. Wang: original Taiwan ranitidine cohortWang: original Taiwan ranitidine cohort · study
  8. Jones: April14,2026 Delaware Zantac orderJones: April14,2026 Delaware Zantac order · court
  9. Jones: January29,2026 Delaware time-limit rulingJones: January29,2026 Delaware time-limit ruling · court
  10. GSK announced agreements with 10 plaintiff firms representing ~80,000 claimants (93% of pending US state-court Zantac cases) to pay up to $2.2 billion in aggregate, with full implementation expected by end of H1 2025; GSK admitted no liability. GSK also agreed to pay $70 million to resolve the Valisure qui tam complaint. Verified from GSK's own press statement.us.gsk.com · Oct 9, 2024
  11. Sanofi agreed to pay more than $100 million to settle ~4,000 Zantac cancer suits in state courts outside Delaware — the first major resolution in the litigation, averaging more than $25,000 per claim per Bloomberg's reporting (republished by Insurance Journal, Apr 23, 2024; deal announced earlier that month). Sanofi denied liability; 70,000+ suits then remained, mostly in Delaware.insurancejournal.com · Apr 23, 2024 · study
  12. MDL 2924 (S.D. Fla., Judge Robin L. Rosenberg) omnibus Daubert order (Doc 6120, 341 pages): ALL defendants' Daubert motions on general causation GRANTED and defendants' summary judgment motion GRANTED — plaintiffs 'fail to produce admissible primary evidence of general causation' that ranitidine causes cancer, ending the federal MDL claims. Verified from the court order itself.gsk.com · Dec 6, 2022 · court
  13. Federal court: February 14, 2023 Zantac order 81

Checked against 10 primary sources by People's Justice editors · Updated

How we make money

People's Justice research team · Updated Oct 4, 2026